K02
Alternative Names: K11002; KO2Latest Information Update: 17 Dec 1998
Price :
$50 *
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Dec 1998 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 19 Nov 1998 Preclinical development for Cancer in USA (Unknown route)